3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
2
Other hematologic neoplasm
2
Lymphoid
2
Tumor-Agnostic
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Glioma
1
Glioblastoma
1
Astrocytoma
1
Interventions
Temozolomide
258
Radiotherapy
147
Bevacizumab
141
Etoposide
68
Cyclophosphamide
68
Carboplatin
66
Magnetic Resonance Spectroscopy
58
Irinotecan
53
Cisplatin
52
Vincristine
45
Filgrastim
43
pembrolizumab
40
Radiosurgery
36
Nivolumab
36
Radiation
34
Topotecan
31
Doxorubicin
30
Specimen Handling
29
sargramostim
28
Lomustine
27
Erlotinib Hydrochloride
27
Peripheral Blood Stem Cell Transplantation
25
Carmustine
25
Thiotepa
24
Everolimus
23
Chemotherapy, Adjuvant
23
Surgical Procedures, Operative
22
Isotretinoin
22
Ipilimumab
22
Melphalan
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Valacyclovir
×
CNS
×
Clear all
NCT00589875
2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2
Completed
52 enrolled
10 charts